Is This Synthetic Biology Pioneer On The Right Track?

Published by
The Street

By Maxx Chatsko Amyris is showing progress in one key area, but it may not be enough. The liquidity bubble of 2021 had many trendy favorites. That included synthetic biology pioneer Amyris (AMRS) – Get Amyris Inc. Report , which has notched several head-turning accomplishments in the laboratory. The industrial biotech company genetically engineers microbes to produce useful chemicals, such as cosmetic or food ingredients. It has yeast strains capable of producing cannabinoid ingredients, which are more commonly associated with cannabis plants. Another makes a cosmetic ingredient that’s commonl…

Read More

See also  Euro technology Here’s the pitch deck that insurtech Quantemplate used to nab $12 million in funding and attract mega insurers like Allianz

Leave a Reply